Genovefa Papanicolaou
Expertise in
6
conditions

Dr. Genovefa Papanicolaou

Infectious Disease
David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center
530 E 74th St, 
New York, NY 
Offers Telehealth
34 Years of Experience
Expertise in
6
conditions
David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center
530 E 74th St, 
New York, NY 

Overview

Genovefa Papanicolaou is an Infectious Disease provider in New York, New York. Dr. Papanicolaou has been practicing medicine for over 34 years is highly rated in 6 conditions, according to our data. Her top areas of expertise are Cytomegalovirus Infection, Sepsis, Cytomegalic Inclusion Disease, and Pneumonia.

Her clinical research consists of co-authoring 138 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Infectious Disease

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
530 E 74th St, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 5 Less Clinical Trials

138 Total Publications

Pneumococcal serotype distribution and outcomes in cancer patients with community-acquired pneumonia: A prospective study using the 15-valent pneumococcal conjugate vaccine serotype specific urinary antigen detection assay.
Pneumococcal serotype distribution and outcomes in cancer patients with community-acquired pneumonia: A prospective study using the 15-valent pneumococcal conjugate vaccine serotype specific urinary antigen detection assay.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: November 16, 2025
Similar Doctors
Expertise in
10
conditions
Dr. Keith Sigel
Infectious Disease
Expertise in
10
conditions
Dr. Keith Sigel
Infectious Disease

St. Luke's-Roosevelt Hospital Center

158 W 124th St, 
New York, NY 
 (3.3 miles away)
332-243-0100
Languages Spoken:
English
See accepted insurances

Keith Sigel is a primary care provider, practicing in Infectious Disease in New York, New York. Dr. Sigel is highly rated in 10 conditions, according to our data. His top areas of expertise are Anal Cancer, HIV/AIDS, Lung Cancer, Gastrostomy, and Endoscopy.

Expertise in
12
conditions
Dr. Jihad Slim
Infectious Disease
Expertise in
12
conditions
Dr. Jihad Slim
Infectious Disease

Saint Michael's Medical Center

111 Central Ave, 
Newark, NJ 
 (11.5 miles away)
973-877-5644
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jihad Slim is an Infectious Disease provider in Newark, New Jersey. Dr. Slim is highly rated in 12 conditions, according to our data. His top areas of expertise are HIV/AIDS, Hepatitis C, COVID-19, Hepatitis, and Gastrostomy.

Expertise in
9
conditions
Dr. Gary Wormser
Infectious Disease
Expertise in
9
conditions
Dr. Gary Wormser
Infectious Disease

Cardiology Consultants

19 Bradhurst Ave, 
Hawthorne, NY 
 (23.8 miles away)
914-493-8865
Languages Spoken:
English
See accepted insurances

Gary Wormser is an Infectious Disease provider in Hawthorne, New York. Dr. Wormser is highly rated in 9 conditions, according to our data. His top areas of expertise are Lyme Disease, Babesiosis, Human Granulocytic Ehrlichiosis, Ehrlichiosis, and Splenectomy.

Frequently Asked Questions about Dr. Genovefa Papanicolaou

How do I make an appointment with Dr. Genovefa Papanicolaou?

You can book an appointment with Dr. Genovefa Papanicolaou by calling their office at 929-476-0294. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Genovefa Papanicolaou a top-rated expert for Cytomegalovirus Infection?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Genovefa Papanicolaou is classified as an Elite expert for Cytomegalovirus Infection, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Genovefa Papanicolaou specialize in?

While Dr. Genovefa Papanicolaou is a Infectious Disease, they have specific expertise in Cytomegalovirus Infection, Sepsis, and Cytomegalic Inclusion Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Genovefa Papanicolaou participate in research or clinical trials?

Yes. Dr. Genovefa Papanicolaou has published 138 articles and abstracts on conditions like Cytomegalovirus Infection. You can view a list of Dr. Genovefa Papanicolaou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Genovefa Papanicolaou accept my insurance?

Dr. Genovefa Papanicolaou accepts most major insurance plans, including Anthem BCBS and Horizon Healthcare. We recommend calling the office directly at 929-476-0294 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papanicolaou's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile